Universitat De Les Illes Balears

Sanifit Therapeutics S.a.

Numat Biomedical, S. L.

Laboratorios Sanifit, S.l.

Laboratories Sanifit, S. L.

Laboratoris Sanifit, S.l.

Numat Medtech, S.l.

Fernando Tur Espinosa

Joan Perello Bestard

Bernat Isern Amengual

Eva Martin Becerra

Maria De Mar Benito Amengual

Irene Lentheric

Paula Mendoza De Las Heras

Eva Tur Tur

Ciriaco Maraschiello De Zuani

Maximo Encabo Alarcon

Félix Grases Freixedas

Antonia Costa Bauza

Rafael M Prieto Almirall

Felix Grases Freixedas

Isabel Gomila Muñiz

Isabel Gomila Muniz

Marta Monjo Cabrer

Joana María Ramis Morey

Joan Perelló Bestard

Rubén Henríquez Paláez

María Del Mar Arriero Sánchez

Eva Martín Becerra

María Del Mar Benito Amengual

Joan Perelló Berstard

Joana Maria Ramis Morey

Maria Del Arriero Sanchez

Ruben Henriquez Palaez

Iréne Lenthéric

Máximo Encabo Alarcón

María Del Mar Arriero SÁNCHEZ

Iréne LENTHÉRIC

María De Mar Benito Amengual

Máximo Encabo ALARCÓN

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups &#x2014;R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

The present invention relates to a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein a compound selected from the group consisting of an IP, an ester of an IP, and/or a pharmaceutically acceptable salt thereof, or a combination thereof, is/are covalently bound to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. The covalent bond between the IP and the metal, metal alloy or metal oxide surface can be further assisted by the use of a linker. An implant according to the invention provides for a modulated and/or improved osseointegrative effect when implanted into a body, such as a mammalian body, by virtue of the coating comprising covalently bound phytate.

Biocompatible implant

This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.

Composition of dialysis liquid comprising crystallisation inhibitor substances

Growing community of inventors

Palma De Mallorca, Spain

Fernando Tur Espinosa